Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M₁ receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

Charlotte Bakker¹, Tim Tasker², Jan Liptrot², Ellen P. Hart¹, Erica S. Klaassen¹, Robert Jan Doll¹, Giles A. Brown³, Alastair Brown², Miles Congreve², Malcolm Weir², Fiona H. Marshall⁴, David M. Cross⁵, Geert Jan Groeneveld¹,⁶* and Pradeep J. Nathan²,⁷,⁸

Abstract

Background: The cholinergic system and M₁ receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M₁ receptor partial agonist HTL0018318 is under development for the symptomatic treatment of Dementia’s including Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB). We investigated the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of multiple doses of HTL0018318 in healthy younger adults and elderly subjects.

Methods: This randomised, double blind, placebo-controlled study was performed, investigating oral doses of 15–35 mg/day HTL0018318 or placebo in 7 cohorts of healthy younger adult (n = 36; 3 cohorts) and elderly (n = 50; 4 cohorts) subjects. Safety, tolerability and pharmacokinetic measurements were performed. Pharmacodynamics were assessed using a battery of neurocognitive tasks and electrophysiological biomarkers of synaptic and cognitive functions.

Results: HTL0018318 was generally well-tolerated in multiple doses up to 35 mg/day and were associated with mild or moderate cholinergic adverse events. There were modest increases in blood pressure and pulse rate when compared to placebo-treated subjects, with tendency for the blood pressure increase to attenuate with repeated dosing. There were no clinically significant observations or changes in blood and urine laboratory measures of safety or abnormalities in the ECGs and 24-h Holter assessments. HTL0018318 plasma exposure was dose-proportional over the range 15–35 mg. Maximum plasma concentrations were achieved after 1–2 h. The apparent terminal half-life of HTL0018318 was 16.1 h (± 4.61) in younger adult subjects and 14.3 h (± 2.78) in elderly subjects at steady state. HTL0018318 over the 10 days of treatment had significant effects on tests of short-term (working) (Continued on next page)
Background

Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) are progressive neurodegenerative disorders caused by complex pathophysiological processes [1], leading to degeneration of the cholinergic neurons in the basal forebrain and their projections to the cortex and the hippocampus [2]. These cholinergic deficits play a key role in the underlying cognitive impairments as well as some of the behavioural and psychiatric symptoms including visual hallucinations [3–7].

The complex pathology of AD and DLB has hampered progress toward a curative treatment. Currently, the only available treatment is symptomatic and consists mostly of acetylcholinesterase inhibitors. Acetylcholinesterase inhibitors (ChEIs) inhibit the breakdown of the neurotransmitter acetylcholine (ACh) and subsequently prolong the availability of ACh at the synapse. This leads to activation of cholinergic muscarinic and nicotinic receptors in the neocortex and hippocampus, which are involved in cognitive function. Despite their ability to improve cognition, ChEIs demonstrate only modest clinical efficacy, likely due to ongoing neurodegeneration of cholinergic neurons in dementia including AD and associated decrease of ACh synthesis, and by a limited dosing range of ChEIs because of side effects including gastrointestinal side effects linked to indirect stimulation of peripheral muscarinic M2 and M3 receptors [8–11]. Therefore, despite efforts to develop disease-modifying treatments for AD, there is a need for improved symptomatic treatments for AD and other dementia’s targeting not only cognitive symptoms but behavioural and psychiatric symptoms. Optimization of the current treatment options can be achieved by targeting post synaptic muscarinic receptors, in particular M1 receptors involved in cognitive function relative to other muscarinic receptors (i.e. M2 and M3 receptors) associated with peripheral side effects. Such selectivity might allow for higher dosing, which could contribute to improved efficacy for certain cognitive and/or behavioural symptoms. Hence selective M1 receptor agonists may be promising drugs for the treatment of cognitive, behavioural and psychological symptoms in psychiatric and neurological disorders (for a review, see Erskine et al. [12]).

The M1 muscarinic acetylcholine receptor (mAChR) is the predominant mAChR in the central nervous system and is highly expressed in the neocortex and hippocampus [13, 14]. Pre-clinical studies suggest M1 agonists can improve cognitive function including learning and memory [15–19]. Consistent with this evidence, muscarinic receptor agonists including the M1/M4 agonist Xanomeline and the M1 agonist GSK1034702 have shown promising early clinical effects [16, 20]. Xanomeline showed improvement in global cognitive function (i.e. ADAS-Cog), general clinical status (i.e. CIBIC+), and behavioural symptoms such as delusions, hallucinations, and agitation [20]. Similarly, the M1 agonist GSK1034702 was shown to improve episodic memory (international shopping list task of the Cogstate battery) in a nicotine abstinence model of cognitive dysfunction [16].

HTL0018318 (ethyl (3-endo)-3-(3-oxo-2,8-diazaspiro [4,5] dec-8-yl)-8-azabicyclo [3.2.1] octane-8-carboxylate hydrochloride), is a partial M1 mAChR agonist that has been developed for the symptomatic treatment of cognitive, behavioural and psychiatric symptoms in dementias including AD and DLB. In pre-clinical studies, HTL0018318 was found to be highly selective for the M1 receptor with an EC50 of approximately 100 nM and with twofold selectivity for the M1 over M4 receptors with no detectable functional agonist activity at human M2 and M3 receptors. Pre-clinical studies have shown HTL0018318 to reverse scopolamine-induced deficits in passive avoidance learning in rats consistent with pro-cognitive effects reported with other M1 agonists on tests of learning and memory. The single ascending dose (SAD) study with HTL0018318 has shown that single doses of HTL0018318 up to 35 mg were relatively well-tolerated in healthy younger adult and elderly subjects [21]. HTL0018318 was absorbed rapidly, peak plasma concentration was typically reached 1–2 h post-dose and the average elimination half-life was 12–16 h. Approximately 30% of the plasma unbound concentration entered the cerebral spinal fluid. No consistent significant effects on exploratory pharmacodynamic (PD) tests were
observed. The SAD study was followed by the current multiple-dose escalation study, in which we aimed to investigate the safety, tolerability, pharmacokinetics (PK) and exploratory PD of HTL0018318 in healthy subjects.

**Methods**

**Design**
This was a double-blind, randomised, placebo-controlled, parallel group study that consisted of 7 cohorts in total: 3 cohorts of 12 younger adult healthy subjects and 4 cohorts of 12 healthy elderly subjects. The study design is shown in Fig. 1. The study was approved by the medical ethics review board of the foundation Beoordeling Ethiek Biomedisch Onderzoek (BEBO, Assen, The Netherlands) and conducted according to the principles of the Declaration of Helsinki and the ICH GCP guidelines [22].

**Participants**
Healthy younger adult subjects aged 18–55 years and healthy elderly subjects aged 65 years and over, both male and female, were enrolled to participate in the study. Subjects were eligible if they were non-smokers, in good health, with a resting systolic blood pressure between 90 and 140 mmHg, diastolic blood pressure between 50 and 90 mmHg and a heart rate between 45 and 100 bpm at screening. Main exclusion criteria were current or past history of any physical, neurological or psychiatric illness and currently on any medication including antihypertensive drugs.

**Investigational product**
HTL0018318, in this study administered as the HCl salt, was administered as a 100 ml oral solution. Water was used as placebo. To mask the difference in taste between HTL0018318 and placebo, a peppermint strip (Listerine) was administered 1 min before and after the administration of HTL0018318. Subjects were not asked if they could guess whether they received HTL0018318 or placebo as the study was a parallel group design with taste related unmasking having minimal impact on unblinding.

Dose levels of 15 mg, 20 mg, 25 mg or placebo were administered in a ratio 9:3 (active:placebo) once a day for 10 consecutive days in both younger adult and elderly subjects. The dose level of 35 mg was only studied in a cohort with elderly subjects (8 subjects on HTL0018318 and 4 subjects on placebo) and administered to 3 subjects (including one replacement); however, lack of tolerability led to a titration regimen of 20 mg HTL0018318 once a day for 5 consecutive days followed by 35 mg HTL0018318 once a day for 10 consecutive days (7 subjects on HTL0018318 and 3 subjects on placebo). Before implementing this new dosing regimen, the protocol was amended and approved.

HTL0018318 dosages were based on the tolerated dose range of 1–35 mg in the SAD study.

**Safety and tolerability assessments**
The investigated safety end points were adverse events (AEs) collected and recorded on the first dosing day, continuing until the follow-up visit, safety laboratory sampled at regular intervals, vital signs and electrocardiogram (ECG) conducted daily pre-dose and 1 h post-dose, and with a higher frequency on the 1st, 5th and 10th dosing day, 24-h Holter registration performed at the 1st and 10th dosing day and pulmonary function tests (PFT). Cholinergically mediated AEs (i.e. AEs with a (possible) relationship to increased cholinergic stimulation) were identified. AEs in this category included; hyperhidrosis, salivary hypersecretion, hypertension, nausea, diarrhoea, vomiting, constipation, insomnia, somnolence, dizziness, muscle spasms, hot flush, cold sweat and piloerection.
Pharmacokinetics assessments
Venous blood samples for PK analysis were obtained pre-dose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 9 h and 12 h post-dose on dosing days 1 and 10. On dosing day 5, blood PK samples were obtained pre-dose and at 1 h, 3 h, 6 h and 9 h post-dose. On the remaining days, only trough samples were taken. Urine for PK analyses was collected up to 24 h after the first drug administration and up to 72 h after the last drug administration. In subjects who were administered 35 mg HTL0018318 according to the up-titration schedule, extra PK samples were collected pre-dose on each day and 1, 3, 6 and 9 h after the 5th administration of 20 mg. Plasma and urine concentrations of HTL0018318 were determined using validated bioanalytical methods involving protein precipitation and liquid chromatography coupled with tandem mass spectrometry. The analytical range of the assay was 0.5–1000 ng/ml.

PK parameters included in the analysis were the maximum observed plasma concentration (Cmax); time to Cmax (tmax); area under the plasma-concentration-time curve (AUC) zero to the last measurement (AUClast); from zero to the end of the dose interval (AUCO-tau) and from zero to infinity (AUCO-inf); time of the minimum concentration (tmin); the minimum concentration within the dosing interval (Cmin); apparent elimination half-life (t1/2); apparent oral clearance (CL/F); apparent volume of distribution (Vz/F); renal clearance (CLR); percentage of dose excreted renally as unchanged drug (Ae%); and coefficient of variation (%CV). Non-compartmental analyses were performed on the PK data using Phoenix 64 build 6.4.0.768 using WinNonlin 6.4. Statistical analysis was performed in R version 3.3.1 (2016-06-21).

Exploratory pharmacodynamic assessments
To assess the acute effects of HTL0018318 on central nervous system (CNS) functioning, exploratory PD tests were performed with use of the NeuroCart, a test battery assessing a wide range of CNS domains, developed to examine the acute PD effects of CNS-active drugs and previously shown to be sensitive to cholinergic modulation [23–27]. A customised set of tasks to detect PD effects to be expected from a cholinergic drug was performed pre-dose, 1 h, 3 h, 5 h and 9 h post-dose on dosing days 1, 5 and 10. On dosing day 1, the pre-dose measurements were performed twice.

The following NeuroCart tests were performed: the adaptive tracking test measured attention and visuomotor coordination; the Milner maze test (MMT) was used to evaluate spatial working memory, learning and executive function; the n-back task was used to assess (short-term) working memory; pupil size was measured to monitor any drug effects on the sympathetic nervous system; synaptic/network activity was assessed using electrophysiology and included resting electroencephalogram (EEG) (power in delta, theta, alpha, beta and gamma bands) and event-related potentials (ERP) (P300 and Mismatch negativity (MMN)); a visual analogue scale (VAS) according to Bond and Lader was used to subjectively assess alertness, mood and calmness; and a VAS nausea was used to evaluate subjective nausea. The Leeds Sleep Evaluation Questionnaire (LSEQ) was used to assess changes in sleep quality. Detailed task descriptions are provided in the supplement methods section.

Saliva production was assessed by measuring the change in weight of three Salivette® dental rolls put into the oral cavity for 3 min. Pulmonary function was measured using the Spirostik (distributed by Accuramed), a PC-based open spirometry system. Vital signs were also analysed.

Statistics
No formal hypothesis testing was conducted. The sample size was chosen based on a compromise between minimising the exposure of human subjects to a new chemical entity and the need to provide sufficient data. Hence, the study was not powered to detect any significant treatment effects of small to moderate effect sizes.

The repeatedly measured PD endpoints on dosing days 1, 5 and 10 were analysed with a mixed model analysis of covariance (ANCOVA) with treatment, time, treatment by time, group, treatment by group, group by time and treatment by group by time as fixed factors and subject as random factor and the average baseline measurement as covariate. Least-square means (LSMs) and 95% confidence intervals (CIs) were estimated from the ANCOVA models. The repeatedly measured PD parameters of the subjects dosed 35 mg according to an up-titration schedule were analysed together with the placebo subjects of the other elderly cohorts to increase the power. The data after the up-titration was analysed with a mixed model ANCOVA with treatment, time and treatment by time as fixed factors, subject as random factor and the average baseline measurement as covariate. All subjects who received at least one dose of study treatment were included in the safety and PD analysis set. PD data of the two subjects who were administered 35 mg HTL0018318 not according to an up-titration schedule were not analysed. The following contrasts were calculated for dosing days 1, 5 and 10 separately for every dose level: HTL0018318 (younger adults + elderly subjects) vs placebo (all placebo subjects pooled together); HTL0018318 (younger adult subjects) vs placebo (younger adult placebo subjects pooled together); and HTL0018318 (elderly subjects) vs placebo (elderly placebo subjects pooled together).
For all outcome parameters, the mean, standard deviation, 95% CI and effect sizes were calculated. All calculations were performed using SAS for windows V9.4 (SAS Institute, Inc., Cary, NC, USA). MMN data were excluded from statistical analysis due to limited data quality and technical issues with stimuli timing and recording. Hence, only resting state EEG power data and P300 data were reported here.

Results

Subjects

A total of 36 healthy younger adult subjects with a mean age of 30 years (range 18–53) and with a mean body mass index (BMI) of 23.7 kg/m² (range 18–31) were enrolled. A total of 50 healthy elderly subjects, with a mean age of 69.9 years (range 65–83) and with a mean BMI of 25.9 kg/m² (range 20.5–32.5) were included. See Fig. 2 for subject disposition flow chart. The AEs leading to withdrawal of six subjects are described below. In one elderly subject the third dose of 25 mg HTL0018318 was not administered due to infection-like symptoms and elevated c-reactive protein. The subject subsequently recovered spontaneously and dosing was resumed.

Safety and tolerability

Multiple doses of 15, 20 and 25 mg HTL0018318 were generally well-tolerated by healthy younger adult and elderly subjects. The dose level of 35 mg without up-titration period was not tolerated by elderly subjects. The 2 subjects dosed with 35 mg without up-titration period were withdrawn from the study due to AEs (hypertension and cold sweat) after the 1st or 2nd administration of HTL0018318. Consequently, it was decided to stop dosing 35 mg without an up-titration period in the remaining subjects of this cohort and to add an up-titration period preceding the 35 mg doses. This was relatively well-tolerated with only mild AEs and no withdrawn subjects. Overall, more subjects dosed with HTL0018318 reported AEs compared to subjects dosed with placebo (Tables 1 and 2). In younger adults,
the number of subjects reporting AEs in general and the number of cholinergically mediated AEs appeared to be treatment-related. However, no clear dose-response relationship was observed. In elderly, the number of subjects reporting AEs in general and the number of cholinergically mediated AEs appeared to be treatment- and dose-related.

The most frequently occurring cholinergically mediated AEs were nausea, hyperhidrosis, chills, cold sweat, somnolence and feeling cold (see Tables 1 and 2).

In total, 6 subjects were withdrawn from the study because of AEs. One elderly subject experienced severe cold sweats and chills after 1 administration of 35 mg HTL0018318 without up-titration period. One elderly subject was withdrawn from the study after 2 administrations of 35 mg HTL0018318 without up-titration period due to hypertension (supine systolic blood pressure of 168/84 mmHg, increase of > 40% from baseline). One elderly subject was withdrawn after 1 administration of 20 mg during the period preceding the 35 mg dose due to a 40% increase of supine blood pressure to 196/99 mg Hg compared to baseline (140/62 mmHg). One subject was withdrawn from further participation after 6 administrations of 25 mg HTL0018318 due to elevated liver enzymes AST (76 U/L) and ALT (127 U/L). The AEs of these 4 subjects were considered to be related to the study drug. One younger adult subject was withdrawn after 4 administrations of 25 mg HTL0018318 because of episodes of bradycardia down to 38 bpm in combination with nausea and fatigue. These episodes of bradycardia were also observed on the 24-h Holter monitoring which was part of the screening and were therefore not considered to be drug-related. One elderly subject was withdrawn because of orthostatic hypotension 24 h after the first 25 mg administration. The supine blood pressure decreased from 106/48 mmHg to 66/37 mmHg. As there was no clear relation to peak plasma HTL0018318 concentration, this AE was not considered to be related to the study drug.

No consistent clinically relevant abnormalities in haematology blood results, urinalysis, ECGs and 24-h Holter monitoring were observed in both younger adult and elderly subjects. No serious AEs or deaths occurred. There were no chemistry blood results that showed an apparent trend toward increased incidence with ascending dose levels of HTL0018318 during the study.

### Pharmacokinetic parameters

The PK parameters and mean concentration-time profiles of HTL0018318 are shown in Figs. 3 and 4. These figures show HTL0018318 arithmetic mean plasma concentration against time of 10 daily oral doses of 15, 20

| MedDRA-preferred term | Placebo n=9 | 15 mg n=9 | 20 mg n=9 | 25 mg n=9 | All HTL0018318 n=27 |
|-----------------------|-------------|-----------|-----------|-----------|--------------------|
| All AEs               | 5 (55.6)    | 8 (88.9)  | 6 (66.7)  | 6 (66.7)  | 20 (74.1)          |
| All cholinergic AEs   | 1 (11.1)    | 1 (11.1)  | 1 (11.1)  | 1 (11.1)  | 8 (29.6)           |
| Nausea                | 0           | 0         | 0         | 1 (3.7)   | 1 (3.7)            |
| Diarrhoea             | 0           | 0         | 0         | 0         | 0                  |
| Vomiting              | 0           | 0         | 0         | 1 (3.7)   | 1 (3.7)            |
| Hypersalivation       | 0           | 0         | 0         | 0         | 0                  |
| Hyperhidrosis         | 0           | 1 (11.1)  | 4 (44.4)  | 3 (33.3)  | 8 (29.6)           |
| Constipation          | 0           | 0         | 0         | 0         | 0                  |
| Chills                | 0           | 1 (11.1)  | 0         | 0         | 1 (3.7)            |
| Cold sweat            | 0           | 0         | 0         | 0         | 0                  |
| Feeling cold          | 0           | 0         | 1 (11.1)  | 0         | 1 (3.7)            |
| Feeling hot           | 0           | 0         | 1 (11.1)  | 0         | 1 (3.7)            |
| Feeling of body temperature change | 0 | 0         | 0         | 0         | 0                  |
| Hot flush             | 0           | 0         | 1 (11.1)  | 2 (22.2)  | 3 (11.1)           |
| Piloerection          | 0           | 0         | 2 (22.2)  | 0         | 2 (7.4)            |
| Peripheral coldness   | 0           | 0         | 0         | 0         | 0                  |
| Insomnia              | 1 (11.1)    | 0         | 0         | 0         | 0                  |
| Dizziness             | 0           | 0         | 1 (11.1)  | 1 (11.1)  | 2 (7.4)            |
| Muscle spasm          | 0           | 1 (11.1)  | 0         | 0         | 1 (3.7)            |

Data are shown as number (percentage) of subjects reporting AEs.
or 25 mg for younger adult subjects (Fig. 3) and additionally mean (± SD) plasma concentrations of 35 mg in elderly subjects (Fig. 4). The absorption was rapid with a median $T_{\text{max}}$ of 1 h post-dose (range 0.5 to 4 h). The oral PK profile was biphasic after $C_{\text{max}}$. The mean (SD) apparent terminal half-life in healthy subjects was 16.1 h (± 4.61) in younger adult subjects and 14.3 h (± 2.78 h) in elderly subjects determined up to 72 h post-dose. A mean accumulation index of 1.32 was seen in younger adult and 1.29 in elderly subjects following the 10th...
dose, in terms of AUC$_{0-24}$. Steady state was reached in approximately two or three doses. The ratio between the mean multiple dose AUC$_{0\text{-}\tau}$ to the AUC$_{0\text{-}\infty}$ after the 1st dose was 1.06 following the 5th and 1.14 following the 10th dose in younger adults and 1.03 following the 5th and 1.07 following the 10th dose in elderly subjects. On average, elderly subjects appeared to have lower oral clearance than the younger adults (mean (SD) CL$_{ss/F}$ 18.3 (± 6.68) L/h in younger adult and 16.0 (± 6.79) L/h in elderly subjects). The inter-individual variability in C$_{\max}$, AUC and $t_{\frac{1}{2}}$ was moderate, with a %CV typically < 30 and not larger than 66 for any variable.

Exposure to HTL0018318 was dose-proportional over the range 15 to 35 mg. Exposure in elderly subjects given 20 mg was higher than expected; however, dose-exposure proportionality did not deviate from linearity assessed using the power model [28]. The reason for higher exposure at 20 mg in elderly subjects could not be determined.

Renal elimination was a major route of clearance. The mean percentage recovery of HTL0018318 over the 24-h dose interval following the 10th dose was 58.1% in younger adults (range 22.3 to 95.3) and 50.4% in elderly subjects (range 25.8 to 95.7%), which represents the minimum absolute oral bioavailability. The mean renal clearance was 8.62–8.84 L/h in younger adults and 6.03–6.23 L/h in elderly subjects.

Central pharmacodynamic biomarkers
HTL0018318 daily dosing for 10 days showed no consistent effects on EEG/ERP, saliva production, LSEQ, pupil size or VAS scores compared to placebo (table in result supplement). Although the study was not powered to detect small to moderate pro-cognitive effects of HTL0018318, some significant differences compared to placebo were observed on a number of cognitive tests including adaptive tracking (a measure of psychomotor function and attention), the n-back test (a measure of working memory) and the Milner Maze Test (a measure of learning and memory).

Adaptive tracking test
Overall, HTL0018318 had no significant effects on the adaptive tracking test in young and elderly subjects across doses and testing days. However, after administration of 20 mg HTL0018318, the time correctly tracked was improved by 3.605%-point (95% CI [0.672–6.539], $p = 0.0167$) compared with placebo, on dosing day 1 in the elderly subjects (see Fig. 5, data shown as estimate of the change from baseline performance.).

N-back test
Overall, an improvement in performance in both younger adult and elderly subjects on the n-back test (0-, 1- and 2-back conditions) was observed following administration of all dose levels of HTL0018318 compared with placebo. The effect on the performance on the most relevant 2-back working memory “accuracy” measure is reported here. In all observations, a higher (number correct-number incorrect)/total was observed indicating better performance. See supplement results section for data on the 0-back and 1-back (accuracy and reaction time) and 2-back (reaction time) conditions.

After administration of 15 mg HTL0018318, the 2-back accuracy score was 0.076 higher on dosing day 1 (95% CI [0.028–0.125], $p = 0.0022$) and 0.069 higher on dosing day 10 (95% CI [0.020–0.118], $p = 0.0058$) compared with placebo. Following administration of 20 mg HTL0018318, the 2-back accuracy score was 0.108 higher on dosing day 1 (95% CI [0.059–0.157], $p =$
0.068 higher on dosing day 5 (95% CI [0.019–0.117], \( p = 0.0073 \)) and 0.066 higher on dosing day 10 (95% CI [0.016–0.115], \( p = 0.0095 \)), compared with placebo. After administration of 25 mg HTL0018318, the 2-back accuracy score was 0.068 higher on dosing day 1 (95% CI [0.020–0.117], \( p = 0.0063 \)) compared with placebo. These data were analysed separately for younger adult and elderly subjects. This is presented in Table 3 and Fig. 6.

**Milner maze test**

Overall, administration of HTL0018318 in both younger adult and elderly subjects was associated with a reduction in total exploratory errors and total moves (on immediate, reversed and delayed conditions) on the Milner maze test (MMT). There was an overall significant treatment effect of HTL0018318 (including dose level 15 mg, 20 mg, 25 mg and 35 mg) on the performance of the MMT immediate and reversed condition.
(MMT immediate exploratory error; MMT immediate total moves; MMT reversed exploratory error; MMT reversed total moves). The data from exploratory errors are reported here. See supplement results section for data on the total moves outcome measure which was generally consistent with the data on exploratory errors for immediate and delayed conditions. Overall, HTL0018318 had no significant or consistent effects on exploratory errors in the Milner Maze delayed condition across doses and days in young and elderly subjects. However, selective effects were observed (see supplementary results).

**MMT immediate: exploratory errors**

HTL0018318 had some significant and consistent effects on exploratory errors in the Milner maze test at the 15 mg 20 mg, 25 mg and 35 mg doses across days, particularly in the elderly subjects. In all observations, a lower number of errors were observed indicating better performance.

Administration of 15 mg HTL0018318 was associated with 3.6 fewer exploratory errors on dosing day 1 (95% CI [−7.1 to −0.2], p = 0.0380), 6.7 fewer exploratory errors on dosing day 5 (95% CI [−10.1 to −3.2], p = 0.0002) and 48 fewer exploratory errors on dosing day 10 (95% CI [−8.2 to −1.3], p = 0.0073), compared with placebo. Following 20 mg HTL0018318, 3.6 fewer exploratory errors were observed on dosing day 5 (95% CI [−7.1 to −0.1], p = 0.0460), compared with placebo. No significant effect was observed after administration of 25 mg HTL0018318 on the number of exploratory errors compared with placebo. Data were analysed separately for younger adult and elderly subjects. These are presented in Table 4 (HTL0018318 compared to placebo, results expressed in exploratory errors) and Fig. 7.

**MMT reversed: exploratory errors**

Overall, HTL0018318 had some significant and consistent effects on exploratory errors in the Milner maze test at the 15 mg 20 mg, 25 mg and 35 mg doses across days, in younger adult and elderly subjects. In all observations, a lower number of errors were observed indicating better performance. Administration of 15 mg HTL0018318 was associated with 1.7 fewer exploratory errors on dosing day 1 (95% CI [−2.9 to −0.4], p = 0.0086), compared with placebo. After administration of 20 mg HTL0018318, 1.4 fewer exploratory errors were observed on dosing day 1 (95% CI [−2.7 to −0.2], p = 0.0275), compared with placebo. Administration of 25 mg HTL0018318 was associated with 2.1 fewer exploratory errors on dosing day 1 (95% CI [−3.3 to −0.9], p = 0.0011) and 1.7 fewer exploratory errors on dosing day 10 (95% CI [−2.9 to −0.4], p = 0.0119), compared with placebo. The MMT reversed condition data was analysed separately for younger adult and elderly subjects. This is presented in Table 5 (HTL0018318 compared to placebo, results expressed in exploratory errors) and Fig. 8.
EEG/ERPs
In general, HTL0018318 had no consistent effects on EEG power. For several EEG bands, some statistically significant effects in subjects treated with HTL0018318 compared with placebo were observed; however, these were not consistent across treatment, electrode position or days of treatment. Similarly, there was no consistent effect of HTL0018318 on P300 amplitude or latency, although a significant improvement in P300 amplitude was noted with the 20 mg dose in the elderly on dosing day 1 (mean difference of 3.670 μV, 95% CI [0.554–6.786], p = 0.0222).

Other pharmacodynamic biomarkers: blood pressure and pulse rate
Systolic and diastolic blood pressure was not consistently higher or lower in the subjects treated with HTL0018318 than in the placebo subjects. However,
some doses of HTL0018318 did demonstrate statistically significant differences versus placebo at some time points. The magnitude and direction of change in blood pressure following HTL008318 treatment was similar for younger adult and elderly subjects. The statistically significant differences in blood pressure on dosing day 1 were relative increases and on dosing day 5 and 10 were relative decreases compared to placebo. This pattern was consistent for supine and standing systolic blood pressure and diastolic blood pressure, but with more significant effects being noted on diastolic blood pressure than on systolic blood pressure.

Mean systolic blood pressure increased up to 8.7 mmHg (95% CI [1.6, 15.8], p = 0.0116, dosing day 1, 25 mg in younger adults) and in mean diastolic blood pressure up to 7.0 mmHg (95% CI [2.4, 11.7], p = 0.0036, dosing day 1, 15 mg in elderly subjects) (Fig. 9a and b, results shown as estimate of the change from baseline.). No evidence of a dose response was observed.

There was a statistically significantly higher pulse rate for the majority of treatment groups versus placebo across duration of dosing, particularly in supine pulse rate and in elderly subjects. The maximum increase in mean supine pulse rate was 10 bpm (95% CI [4.7–15.3], p = 0.0007, dosing day 5 of 35 mg regimen by up-titration). Similar results were observed in standing pulse rate. See supplement results section for data on systolic and diastolic blood pressure and pulse rate.

**Discussion**

We previously reported the safety and tolerability of HTL0018318 following ascending doses in healthy subjects [21]. In this study, we report the safety and tolerability of HTL0018318 following multiple ascending dosing over 10 days in healthy younger adult and elderly subjects. We also report exploratory PD effects on biomarkers of cognitive function. Overall, HTL0018318 was generally well tolerated at the doses tested and there was some evidence for pro-cognitive effects, particularly on tests of short term (working) memory and learning.

Systemic exposure of HTL0018318 showed dose-proportional increases and reproducible PK in the 15–35 mg dose range. The plasma concentrations of HTL0018318 reached a maximum typically 1–2 h post-dose and the apparent half-life was approximately 16 h in younger adult subjects and 14 h in elderly subjects. Elimination of unchanged drug in urine was a major pathway with renal clearance being similar to the age-adjusted glomerular filtration rate. PK characteristics were expected based on the results of the SAD study [21]. Overall, these data suggest that HTL0018318 has a PK profile consistent with a once daily regimen with no clear PK differences between healthy younger adult and elderly subjects.

Multiple doses of HTL0018318 up to 25 mg were well-tolerated and associated with mild and moderate treatment-related cholinergically mediated AEs (reported subjectively) in healthy younger adult and elderly

---

**Table 4 Effects of HTL0018318 on the performance of the Milner maze test immediate condition**

| Parameter | Younger adults | | | | Elderly | | | |
|-----------|----------------|---|---|---|---|---|---|---|
|           | Day 1 | Day 5 | Day 10 | Day 1 | Day 5 | Day 10 | Day 1 | Day 5 | Day 10 |
| 15 mg HTL0018318 | MMTImm: Expl Error | –1.2 | –1.8 | –2.6 | –6.1 | –11.5 | –7.0 |
|              | (-6.1, 3.7) | (-6.7, 3.1) | (-7.5, 2.4) | (-10.8, -1.3) | (-16.3, -6.7) | (-11.8, -2.1) |
|              | p = 0.6303 | p = 0.4678 | p = 0.3050 | p = 0.0133 | p < .0001 | p = 0.0052 |
|              | ES = 0.23 | ES = 0.34 | ES = 0.49 | ES = 1.15 | ES = 2.19 | ES = 1.32 |
| 20 mg HTL0018318 | MMTImm: Expl Error | –0.9 | –0.4 | 3.3 | –3.1 | –6.7 | –4.3 |
|              | (-5.9, 4.1) | (-5.4, 4.6) | (-1.7, 8.3) | (-7.9, 1.7) | (-11.5, -1.9) | (-9.2, 0.5) |
|              | p = 0.7204 | p = 0.8637 | p = 0.1930 | p = 0.2061 | p = 0.0066 | p = 0.0802 |
|              | ES = 0.17 | ES = 0.08 | ES = 0.63 | ES = 0.59 | ES = 1.28 | ES = 0.83 |
| 25 mg HTL0018318 | MMTImm: Expl Error | 2.6 | 3.6 | 1.4 | –4.4 | –7.7 | –4.8 |
|              | (-2.4, 7.5) | (-1.4, 8.6) | (-3.6, 6.4) | (-9.3, 0.4) | (-12.6, -2.7) | (-9.9, 0.3) |
|              | p = 0.3047 | p = 0.1565 | p = 0.5720 | p = 0.0718 | p = 0.0025 | p = 0.0632 |
|              | ES = 0.49 | ES = 0.69 | ES = 0.27 | ES = 0.84 | ES = 1.46 | ES = 0.92 |
| (20 + 35 mg) HTL0018318 | MMTImm: Expl Error | –8.9 | –8.2 | –1.6 | –8.9 | –8.2 | –1.6 |
|              | (-15.7, -2.1) | (-15.0, -1.4) | (-8.4, 5.2) | (-15.7, -2.1) | (-15.0, -1.4) | (-8.4, 5.2) |
|              | p = 0.0118 | p = 0.0196 | p = 0.6317 | p = 0.0118 | p = 0.0196 | p = 0.6317 |
|              | ES = 1.32 | ES = 1.22 | ES = 0.24 | ES = 1.32 | ES = 1.22 | ES = 0.24 |

Mean estimated difference (95% CI), p-value, effect size
subjects. The highest dose level of 35 mg tested in 2 participants without an up-titration period was not tolerated by elderly subjects; however, this dose was generally well tolerated with the dose titration regimen. In the SAD study, the severity of the AEs was lower, although in the SAD study 3 of the 9 elderly subjects dosed with 35 mg had an increase in blood pressure and more cholinergically mediated AEs compared with other dose levels, suggesting a lower tolerability at this high dose.

Clinically relevant hypertension (an increase of > 40% compared to the baseline measurement or a blood pressure > 180/115 mmHg) occurred in 3 elderly subject following 20 mg, 25 mg or 35 mg without up-titration, which is comparable to the 5 (out of 57) elderly subjects presenting with increased blood pressure in the SAD study [21]. The observed increases in systolic blood pressure of up to 4.6 mmHg in the elderly and up to 8.7 mmHg in the younger adult subjects in the current
study and increases up to 11.9 mmHg in the SAD study were both modest increases and showed no dose-dependency. The mean supine pulse rate was significantly higher in the majority of treatment groups in the current study (up to 9.6 bpm in the elderly and up to 7.5 bpm in the younger adult subjects) and some evidence for dose dependency. However, it should be noted that there was a reduction in pulse rate post-dose in the placebo treated participants and therefore the higher pulse rate in the HTL0018318 groups demonstrated less of a reduction (relative to placebo) rather than an increase in pulse rate from baseline with HTL0018318 treatment. While the exact mechanisms associated with the blood pressure and pulse rate changes are not known, it is possible that this may be related to M1-mediated modulation of postganglionic sympathetic neurons that innervate the heart [29]. Additionally, there appeared to be a decrease of the cholinergic side effects that innervate the heart [29].

Table 5: Effects of HTL0018318 on the performance of the Milner maze test reversed condition

| Parameter | Younger adults | | Elderly | | |
|-----------|----------------|----------------|----------------|----------------|----------------|
|           | Day 1 | Day 5 | Day 10 | Day 1 | Day 5 | Day 10 |
| HTL0018318 | 15 mg | | | 20 mg | | |
| MMTR: Expl Error | | | | | | |
| –1.9 | –0.5 | –1.0 | –1.4 | –1.9 | –0.7 |
| (–3.7, –0.1) | (–2.2, 1.3) | (–2.8, 0.8) | (–3.2, 0.3) | (–3.6, –0.2) | (–2.5, 1.0) |
| p = 0.0359 | p = 0.0101 | p = 0.0322 | p = 0.04115 |
| ES = 1.00 | ES = 0.24 | ES = 0.52 | ES = 0.76 | ES = 1.00 | ES = 0.38 |
| 20 mg HTL0018318 | | | | | | |
| MMTR: Expl Error | | | | | | |
| –1.1 | –0.0 | 0.3 | –1.8 | –2.0 | –1.3 |
| (–2.9, 0.7) | (–1.8, 1.7) | (–1.5, 2.1) | (–3.5, –0.0) | (–3.7, –0.2) | (–3.0, 0.5) |
| p = 0.2347 | p = 0.09592 | p = 0.7500 | p = 0.0487 | p = 0.0284 | p = 0.1593 |
| ES = 0.57 | ES = 0.02 | ES = 0.15 | ES = 0.92 | ES = 1.03 | ES = 0.66 |
| 25 mg HTL0018318 | | | | | | |
| MMTR: Expl Error | | | | | | |
| –2.2 | –0.1 | –1.4 | –2.0 | –1.7 | –1.9 |
| (–3.9, –0.4) | (–1.9, 1.7) | (–3.2, 0.4) | (–3.8, –0.3) | (–3.5, 0.1) | (–3.7, –0.1) |
| p = 0.0174 | p = 0.093 | p = 0.1219 | p = 0.0217 | p = 0.0577 | p = 0.0431 |
| ES = 1.14 | ES = 0.04 | ES = 0.75 | ES = 1.08 | ES = 0.90 | ES = 0.99 |
| (20 + 35 mg) HTL0018318 | | | | | | |
| MMTR: Expl Error | | | | | | |
| –2.9 | –3.3 | –2.6 | –2.9 | –3.3 | –2.6 |
| (–5.7, –0.1) | (–6.1, –0.5) | (–5.4, 0.2) | (–5.7, –0.1) | (–6.1, –0.5) | (–5.4, 0.2) |
| p = 0.0457 | p = 0.0230 | | p = 0.0718 |
| ES = 1.05 | ES = 1.20 | ES = 0.93 |

Mean estimated difference (95% CI), p-value, effect size

In general, there were no consistent effects on the electrophysiological biomarkers, although this is likely to have been due to poor quality of data and contamination of the P300 data due to a voltage from the trigger pulses leading to high variability. Furthermore, many data sets had to be partially or fully removed due to the artefact (or missing data). This reduced the usable sample considerably reducing the statistical power of the analysis. Hence, these data should be interpreted with caution when interpreting central PD effects measured with EEG/ERP biomarkers including P300.

HTL0018318 over 10 days of treatment was associated with improvements in number of cognitive tests including adaptive tracking in elderly subjects (a measure of psychomotor function and sustained attention), the n-back test in both younger adults and elderly subjects (a measure of working memory) and the MMT in elderly subjects (a measure of learning and memory). Overall, HTL0018318 had more consistent effects across cognitive domains in the elderly compared to younger adults, although the study was not adequately powered to investigate differential effects between the two groups. The magnitude of effects on adaptive tracking (i.e. 3.6%-point improvement) was comparable to that previously reported with Donepezil (10 mg) in healthy subjects [23] but were only observed at the 20 mg dose and only on dosing day 1 in elderly subjects suggesting that effects on psychomotor speed and sustained attention were not robust and consistently modulated by M1 receptor.
modulation with HTL0018318. This is consistent with the lack of effects we previously reported with the M₁ agonist HTL0009936 on adaptive tracking performance. It is possible that cholinergic and M₁ receptor modulation of attentional processing may depend on “attentional effort” or activation of attentional systems by motivation, particularly in the face of challenges such as distractors where a high level of attentional control is needed [30]. In this context, the adaptive tracking task may have not been challenging enough to require sufficient attentional effort for M₁ activation to modulate performance. The effects on tests of memory (n-back and MMT) were however more consistent in younger adult and elderly subjects across doses and over the 10 days of treatment with clinically relevant effects of moderate to large effect sizes. These effects in healthy adults.
normal subjects (presumably with minimal cholinergic dysfunction) are encouraging and may suggest M₁ receptor modulation may have significant effects on learning and memory in disorders of cholinergic dysfunction such as AD and other dementias. The n-back test is a working memory test associated with prefrontal function [31, 32], while the MMT is a learning and memory test associated with hippocampal function [33]. Both the prefrontal cortex and hippocampus are areas rich in muscarinic M₁ receptors [13, 34]. The sensitivity of these tests to muscarinic (and M₁) receptor modulation is supported by previous studies with the non-selective muscarinic antagonist scopolamine and the M₁ antagonist biperiden which have been shown to impair performance on tests comparable to the n-back test (45, 46) and MMT (47). The findings of the current study demonstrating positive
effects of HTL0018318 on tests of short-term memory and learning are also consistent with the pre-clinical [35, 36] and clinical studies [16, 37] that have similarly shown improvements tests of learning and memory with selective M₁ receptor agonists. These findings, while preliminary, provide encouraging data in support of the development of HTL0018318 for cognitive dysfunction in AD and other dementias.

The effects of HTL0018318 was also examined on other PD markers including saliva production, LSEQ, pupil size or VAS scores, but overall no significant changes were observed (table in result supplement). While our data showed no effects on saliva production, hypersalivation was observed in other studies investigating other less selective M₁ mAChR agonists [16, 38–40] and could be explained by their relatively small effects on the M₃ receptors [40]. The observation in the current study confirms the selectivity of HTL0018318 for muscarinic M₁ receptors.

Limitations
There are some limitations of the study that warrant discussion. This study was primarily a safety and tolerability study and the PD measurements were exploratory. As such, these data need to be interpreted with caution, given the small sample size and the lack of power in the study to detect pro-cognitive effects of small to moderate magnitude. While effect sizes were calculated to nuance the PD results calculated by the statistic model (table in result supplement), it is possible that the small sample size could over- or underestimate the pro-cognitive effects of HTL0018318. As discussed above, the EEG/ERP were of poor data quality driven by a voltage noise from the trigger pulses leading to high variability and significant loss of data. Hence, no definite conclusions can be made with regard to the absence of effects of HTL0018318 on the EEG and ERP biomarkers of cognitive function.

Conclusions
In conclusion, HTL0018318 was generally well-tolerated in multiple doses up to 25 mg/day and dosed up to 10 days (in adult and elderly subjects) or up to 15 days according to a titration regimen of 20 mg/day for 5 days followed by 35 mg/day for 10 days in elderly subjects. The multiple dose PK of HTL0018318 were well-characterised. Treatment-related AEs including choliner-gically mediated AEs were mild and transient. Modest changes in blood pressure were observed after the first dose administration, which returned to normal after multiple doses. Consistent and pro-cognitive effects of moderate to large magnitude on short-term memory and learning were demonstrated across the dose range over the 10 days of treatment providing encouraging data in support of the development of HTL0018318 for cognitive dysfunction in dementias.

Abbreviations
%CV: Coefficient of variation; ACh: Acetylcholine; AD: Alzheimer’s disease; Ae%: Percentage of dose excreted renally as unchanged drug; AEs: Adverse events; ANCOVA: Analysis of covariance; AUC: Area under the plasma-concentration-time curve; AUC₁₀⁻∞: AUC from zero to infinity; AUC₁₀⁻τ: AUC from zero to the end of the dose interval; AUC₁₅₀⁻τ: AUC from zero to the last measurement; BMI: Body mass index; ChEIs: Acetylcholinesterase inhibitors; CI: Confidence intervals; CL/F: Apparent oral clearance; CLr: Renal clearance; Cₘ₉₅: Maximum observed plasma concentration; Cₘ₉₇: The minimum concentration; CNS: Central nervous system; DLB: Dementia with Lewy bodies; ECG: Electrocardiogram; EEG: Electroencephalogram; ERP: Event-related potentials; LSEQ: Leeds Sleep Evaluation Questionnaire; LSMs: Least-square means; mAChR: Muscarinic acetylcholine receptor; MMN: Mismatch negativity; MMT: Milner maze test; PD: Pharmacodynamics; PFT: Pulmonary function tests; PK: Pharmacokinetics; SAD: Single ascending dose; t₁/₂: Apparent elimination half-life; tₘ₉₇: Time of the last quantifiable concentration; tₘ₉₅: Time to Cₘ₉₅; VAS: Visual analogue scale; Vz/F: Apparent volume of distribution

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13195-021-00816-5.

Additional file 1.

Acknowledgements
The bioanalysis of HTL0018318 was performed by Irene Morelli (York Bioanalytical Solutions, York, UK). The script for the N-back task was downloaded from the E-prime website (http://steppsy.cmue.edu/scripts-plus) and was adapted for the use in this study.

Safety update
Currently clinical development with HTL0018318 is voluntarily suspended pending the investigation of an unexpected toxicology finding in an animal study involving non-human primates. This voluntary suspension is not based on any human findings.

Authors’ contributions
CB was the project leader and research physician of the study, TT was the medical expert during the study, JL was the programme director, EH was senior project leader, PK performed the statistical analysis, RD was involved in the EEG analysis, DC was involved in the PK analysis, GJG was the principal investigator of the study and PN was involved in the data analysis and interpretation and substantially contributed to writing this paper. All authors contributed in writing and/or reviewing the manuscript. All authors read and approved the final manuscript.

Authors’ information
Not applicable.

Funding
This study was sponsored by Sosei Heptares and Allergan, its licence partner for HTL0018318.

Availability of data and materials
Availability of data and materials: The datasets generated during and/or analysed during the current study are filed in EudraCT and are not publicly available (in accordance with the regulations for Phase 1 data). Further information is available from the corresponding author on reasonable request.

Code availability: The model code is available upon request.

Declarations
Ethics approval and consent to participate
The study was approved by the medical ethics review board of the foundation Beoordelings Ethiek Biomedisch Onderzoek (BEO, Assen, The Netherlands).
Consent for publication
Not applicable.

Competing interests
TT, JL, GB, AB, MC, MW, FM and PN all are currently, or have been, paid employees of SH and have owned stock in the company; DC is a paid independent consultant for SH.

Author details
1Centre for Human Drug Research (CDHR), Zemikdefreef 8, 2332 CL Leiden, The Netherlands. 2Sosei Heptares, Steenmetz Building, Granta Park, Great Abington, Cambridge CB21 6DG, UK. 3Owls Therapeutics Ltd, Oxford, UK. 4Merck Sharp & Dohme Limited, London, UK. 5Cross Pharma Consulting Limited, Cambridge, UK. 6Leiden University Medical Centre, Leiden, The Netherlands. 7Department of Psychiatry, University of Cambridge, Cambridge, UK. 8School of Psychological Sciences, Monash University, Melbourne, Australia.

Received: 25 September 2020 Accepted: 23 March 2021
Published online: 21 April 2021

References
1. Kumar A, Singh A, Elavali. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67(2):195–203. https://doi.org/10.1016/j.pharep.2014.09.004.
2. Potter PE, Rauschkolb PK, Pandya Y, Sue LI, Sabbagh MN, Walker DG, Beach TG. Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease. Acta Neuropathol. 2011;122(1):49–60. https://doi.org/10.1007/s00401-011-0831-1.
3. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572–80. https://doi.org/10.1002/ana.410300410.
4. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Medley-Whitey ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC. Early Abeta accumulation and progressive synaptic loss, glossy, and tangle formation in AD brain. Neurology. 2004;62(6):925–31. https://doi.org/10.1212/01.WNL.0000151115.98965.07.
5. Berg L, McKeel DW Jr, Miller JP, Baty J, Morris JC. Neuropathological indexes of Alzheimer’s disease in demented and non-demented persons aged 80 years and older. Arch Neurol. 1993;50(4):249–58. https://doi.org/10.1001/aarch.1993.00400400110008.
6. Wilcock GK, Esiri MM. Plaques, tangles and dementia. A quantitative study. J Neurol Sci. 1982;56(2–3):343–56. https://doi.org/10.1016/0022-510X(82)90155-1.
7. Perry JK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn. 1995;28(3):240–58. https://doi.org/10.1016/0278-2626(95)90032-4.
8. Lanctot KL, Herrmann N, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a meta-analysis. J Neurol Neurosurg Psychiatry. 2012;83(6):665–73. https://doi.org/10.1136/jnnp.2011.24651.041888.x.
9. Berman KF, Reba RC. The distribution of cerebral muscarinic acetylcholine receptors in vivo: a comparative autoradiographic study. J Neurochem. 1995;64(4):1888–91. https://doi.org/10.1006/jnch.1995.5643.
10. Weinberger DR, Gibson R, Coppola R, Jones DW, Molchan S, Sunderland T, Berman RF, Reba RC. The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. A controlled study with 123I-OHβC and single photon emission computed tomography. Arch Neurol. 1991;48(2):169–76. https://doi.org/10.1001/archneur.1991.0040061018.
11. Lange HS, Cannon CE, Drott JT, Kuduk SD, Uslaner JM. The M1 muscarinic positive allosteric modulator POCA improves performance on translatable tests of memory and attention in rhesus monkeys. J Pharmacol Exp Ther. 2015;355(3):442–50. https://doi.org/10.1124/jpet.115.2236712.
12. Nathan PJ, Watson J, Lund J, Davies CH, Peters G, Dodds CM, Swirski B, Lawrence P, Bentley GD, O’Neill BV, Robertson J, Watson S, Jones GA, Maruff P, Croft RJ, Laruelle M, Bullmore ET. The potent M1 receptor allosteric agonist GS1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacol. 2013;16(4):721–31. https://doi.org/10.1017/S1476538112000752.
13. Watt ML, Schober DA, Hitchcock S, Liu B, Chestfield AK, McKinnie D, Felder CC. Pharmacological characterization of m5 muscarinic acetylcholine receptor-selective partial orthosteric agonist. J Pharmacol Exp Ther. 2011;338(2):622–32. https://doi.org/10.1124/jpet.110.182063.
14. Ruske AC, White KG. Facilitation of memory performance by a novel muscarinic agonist in young and old rats. Pharmacol Biochem Behav. 1999;63(4):663–7. https://doi.org/10.1016/S0091-3057(99)00037-4.
15. Leaderbrand K, Chen HJ, Corcoran KA, Gueldes AL, Jovaisaik V, Wess J, et al. Muscarinic acetylcholine receptors act in synergy to facilitate learning and memory. Learn Mem. 2016;23(11):631–8.
16. Bodick NC, Offen WW, Levey AJ, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollesford GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM. Effects of xanomeline, a selective muscarinic agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54(4):465–73. https://doi.org/10.1001/archneur.1997.00550160091022.
17. Bakker C, Tasker T, Liptrot J, Hart EP, Klaassen ES, Prins S, et al. First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL001381A, a novel M1(-)-receptor partial agonist for the treatment of dementia. Br J Clin Pharmacol. 2020.
18. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.
19. Baakman AC, T Hart E, Kay DG, Stevens J, Klaassen ES, Maelicke A, et al. First in human study with a produg of galantamine: improved benefit-risk ratio? Alzheimer’s Disease. 2016;21(13–22. doi: https://doi.org/10.1016/j.jcel.2015.12.003.
20. Alvarez-Jimenez R, Hart EP, Prins S, de Kam M, van Gerven JMA, Cohen AF, Groenewold GJ. Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: cognitive and (electro) physiological responses. Br J Clin Pharmacol. 2018;84(5):888–99. https://doi.org/10.1111/bcp.13507.
21. Rombouts SA, Barkhof F, Van Meel CS, Scheltens P. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):665–71. https://doi.org/10.1136/jnnp.73.6.665.
22. Babiloni C, Del Percio C, Bordet R, Bournier JL, Bentivoglio M, Payoux P, et al. Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer’s disease patients. Clin Neurophysiol. 2013;124(5):837–50. https://doi.org/10.1016/j.clinph.2012.09.017.
23. Dierks T, Frolich L, Ihl R, Maurer K. Event-related potentials and psychopharmacology. Cholinergic modulation of P300. Psychopharmacology. 1994;117(2):72–7. https://doi.org/10.1007/BF00274582.
24. Gough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Information J. 1995;29(3):1039–48. https://doi.org/10.1177/009286159502901426.
25. Hardouin SN, Richardson KN, Zimmerman A, Hamilton SE, Feigl EO, Nathan AM. Altered cardiovascular responses in mice lacking the M1 muscarinic acetylcholine receptor. J Pharmacol Exp Ther. 2002;301(1):129–37. https://doi.org/10.1124/jpet.301.1.129.
26. Sarter M, Lustig C. Forebrain cholinergic signaling: wired and phasic, not tonic, and causing behavior. J Neurosci. 2020;40(4):712–9. https://doi.org/10.1525/JNEUROSCI.1305-19.2019.
31. Tsuchida A, Fellows LK. Lesion evidence that two distinct regions within prefrontal cortex are critical for n-back performance in humans. J Cogn Neurosci. 2009;21(12):2263–75. https://doi.org/10.1162/jocn.2008.21172.

32. Yaple ZA, Stevens WD, Arsalidou M. Meta-analyses of the n-back working memory task: fMRI evidence of age-related changes in prefrontal cortex involvement across the adult lifespan. Neuroimage. 2019;196:6–31. https://doi.org/10.1016/j.neuroimage.2019.03.074.

33. Milner B. Visually-guided maze learning in man: effects of bilateral hippocampal, bilateral frontal, and unilateral cerebral lesions. Neuropsychologia. 1965;3(4):317–38. https://doi.org/10.1016/0028-3932(65)90005-9.

34. Levey AI. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 1993;52(5-6):441–8. https://doi.org/10.1016/0024-3205(93)90300-R.

35. Dennis SH, Pasqui F, Colvin EM, Sanger H, Mogg AJ, Felder CC, et al. Activation of muscarinic M1 acetylcholine receptors induces long-term potentiation in the hippocampus. Cereb Cortex. 2016;26(1):414–26.

36. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron. 2006;49(5):671–82. https://doi.org/10.1016/j.neuron.2006.01.020.

37. Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). Alzheimer Dis Assoc Disord. 1998;12(4):304–12. https://doi.org/10.1097/00002099-199812000-00010.

38. Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, et al. Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer’s disease. Alzheimer’s Dementia. 2018;4:173–81.

39. Sramek JJ, Hurley DJ, Wardle TS, Satterwhite JH, Houriati J, Dies F, Cutler NR. The safety and tolerance of xanomeline tartrate in patients with Alzheimer’s disease. J Clin Pharmacol. 1995;35(8):800–6. https://doi.org/10.1002/j.1552-4604.1995.tb04123.x.

40. Wienrich M, Meier D, Ensinger HA, Gaida W, Raschig A, Walland A, Hammer R. Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man. Life Sci. 2001;68(22–23):2593–600. https://doi.org/10.1016/S0024-3205(01)01057-8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.